Trial Outcomes & Findings for Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma (NCT NCT03108495)

Last Updated: 2026-07-31

Results Overview

To evaluate the efficacy of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

Recruitment status

TERMINATED

Study phase

PHASE2

Target enrollment

210 participants

Primary outcome timeframe

Up to 60 months

Results posted on

2026-07-31

Participant Flow

Cohorts 1, 2, 3 \& 4 refer to the initial treatment. Cohort 5 refers to participants who had progressed following the initial treatment and were retreated with a second TIL regimen. Data are captured in the retreatment period for Cohort 5.

Participant milestones

Participant milestones
Measure	Cohort 1 LN-145 monotherapy in participants who have progressed during or following systemic therapy; this cohort is no longer open for enrollment.	Cohort 2 LN-145 monotherapy in participants who have previously received a PD-1/PD-L1 checkpoint inhibitor either as monotherapy or combination therapy.	Cohort 3 LN-145 in combination with pembrolizumab in participants who have not received any therapies other than prior chemoradiation or surgery for loco-regional disease.	Cohort 4 LN-145 monotherapy in previously enrolled participants who do not meet requirements for inclusion in the other study cohorts; this cohort is not open for enrollment.	Cohort 5 LN-145 monotherapy as a re-treatment.
Initial Treatment STARTED	100	62	32	16	0
Initial Treatment Participants Infused With TIL	74	42	26	10	0
Initial Treatment COMPLETED	7	0	1	1	0
Initial Treatment NOT COMPLETED	93	62	31	15	0
Retreatment STARTED	0	0	0	0	6
Retreatment Participants Infused With TIL	0	0	0	0	2
Retreatment COMPLETED	0	0	0	0	0
Retreatment NOT COMPLETED	0	0	0	0	6

Reasons for withdrawal

Reasons for withdrawal
Measure	Cohort 1 LN-145 monotherapy in participants who have progressed during or following systemic therapy; this cohort is no longer open for enrollment.	Cohort 2 LN-145 monotherapy in participants who have previously received a PD-1/PD-L1 checkpoint inhibitor either as monotherapy or combination therapy.	Cohort 3 LN-145 in combination with pembrolizumab in participants who have not received any therapies other than prior chemoradiation or surgery for loco-regional disease.	Cohort 4 LN-145 monotherapy in previously enrolled participants who do not meet requirements for inclusion in the other study cohorts; this cohort is not open for enrollment.	Cohort 5 LN-145 monotherapy as a re-treatment.
Initial Treatment Did not receive TIL	26	20	6	6	0
Initial Treatment Death	63	34	17	9	0
Initial Treatment Lost to Follow-up	2	3	0	0	0
Initial Treatment Withdrawal by Subject	2	4	1	0	0
Initial Treatment Study Terminated by Sponsor	0	1	7	0	0
Retreatment Did not receive TIL	0	0	0	0	4
Retreatment Death	0	0	0	0	2

Baseline Characteristics

Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Cohort 1 n=74 Participants LN-145 monotherapy in participants who have progressed during or following systemic therapy; this cohort is no longer open for enrollment.	Cohort 2 n=42 Participants LN-145 monotherapy in participants who have previously received a PD-1/PD-L1 checkpoint inhibitor either as monotherapy or combination therapy.	Cohort 3 n=26 Participants LN-145 in combination with pembrolizumab in participants who have not received any therapies other than prior chemoradiation or surgery for loco-regional disease.	Cohort 4 n=10 Participants LN-145 monotherapy in previously enrolled participants who do not meet requirements for inclusion in the other study cohorts; this cohort is not open for enrollment.	Cohort 5 n=2 Participants LN-145 monotherapy as a re-treatment.	Total n=154 Participants Total of all reporting groups
Age, Categorical Initial Treatment · <=18 years	0 Participants n=74 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	1 Participants n=42 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=26 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=10 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	1 Participants n=152 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Age, Categorical Initial Treatment · Between 18 and 65 years	69 Participants n=74 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	37 Participants n=42 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	23 Participants n=26 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	10 Participants n=10 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	139 Participants n=152 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Age, Categorical Initial Treatment · >=65 years	5 Participants n=74 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	4 Participants n=42 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	3 Participants n=26 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=10 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	12 Participants n=152 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Age, Categorical Retreatment · <=18 years	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Age, Categorical Retreatment · Between 18 and 65 years	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	2 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	2 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Age, Categorical Retreatment · >=65 years	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Age, Continuous Initial Treatment	44 Years n=74 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	46.5 Years n=42 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	46.5 Years n=26 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	46.5 Years n=10 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	—	45 Years n=152 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Age, Continuous Retreatment	—	—	—	—	49.5 Years n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	49.5 Years n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Sex: Female, Male Initial Treatment · Female	74 Participants n=74 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	42 Participants n=42 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	26 Participants n=26 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	10 Participants n=10 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	152 Participants n=152 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Sex: Female, Male Initial Treatment · Male	0 Participants n=74 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=42 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=26 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=10 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=152 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Sex: Female, Male Retreatment · Female	—	—	—	—	2 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	2 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Sex: Female, Male Retreatment · Male	—	—	—	—	0 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Ethnicity (NIH/OMB) Initial Treatment · Hispanic or Latino	5 Participants n=74 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	7 Participants n=42 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	4 Participants n=26 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	1 Participants n=10 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	17 Participants n=152 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Ethnicity (NIH/OMB) Initial Treatment · Not Hispanic or Latino	60 Participants n=74 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	35 Participants n=42 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	22 Participants n=26 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	7 Participants n=10 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	124 Participants n=152 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Ethnicity (NIH/OMB) Initial Treatment · Unknown or Not Reported	9 Participants n=74 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=42 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=26 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	2 Participants n=10 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	11 Participants n=152 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Ethnicity (NIH/OMB) Retreatment · Hispanic or Latino	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Ethnicity (NIH/OMB) Retreatment · Not Hispanic or Latino	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	2 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	2 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Ethnicity (NIH/OMB) Retreatment · Unknown or Not Reported	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Race (NIH/OMB) Initial Treatment · American Indian or Alaska Native	0 Participants n=74 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=42 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=26 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=10 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=152 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Race (NIH/OMB) Initial Treatment · Asian	4 Participants n=74 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	2 Participants n=42 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	3 Participants n=26 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=10 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	9 Participants n=152 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Race (NIH/OMB) Initial Treatment · Native Hawaiian or Other Pacific Islander	0 Participants n=74 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=42 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=26 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=10 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=152 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Race (NIH/OMB) Initial Treatment · Black or African American	2 Participants n=74 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	3 Participants n=42 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=26 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=10 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	5 Participants n=152 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Race (NIH/OMB) Initial Treatment · White	58 Participants n=74 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	33 Participants n=42 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	23 Participants n=26 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	9 Participants n=10 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	123 Participants n=152 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Race (NIH/OMB) Initial Treatment · More than one race	0 Participants n=74 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=42 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=26 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=10 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=152 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Race (NIH/OMB) Initial Treatment · Unknown or Not Reported	10 Participants n=74 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	4 Participants n=42 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=26 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	1 Participants n=10 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	15 Participants n=152 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Race (NIH/OMB) Retreatment · American Indian or Alaska Native	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Race (NIH/OMB) Retreatment · Asian	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Race (NIH/OMB) Retreatment · Native Hawaiian or Other Pacific Islander	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Race (NIH/OMB) Retreatment · Black or African American	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Race (NIH/OMB) Retreatment · White	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	2 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	2 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Race (NIH/OMB) Retreatment · More than one race	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Race (NIH/OMB) Retreatment · Unknown or Not Reported	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Region of Enrollment Netherlands	8 Participants n=74 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=42 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=26 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=10 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	8 Participants n=152 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Region of Enrollment United States	40 Participants n=74 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	35 Participants n=42 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	26 Participants n=26 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	9 Participants n=10 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	1 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	1 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Region of Enrollment United Kingdom	7 Participants n=74 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=42 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=26 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=10 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	7 Participants n=152 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Region of Enrollment France	4 Participants n=74 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=42 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=26 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	1 Participants n=10 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	5 Participants n=152 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Region of Enrollment Switzerland	3 Participants n=74 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	1 Participants n=42 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=26 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=10 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	1 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	1 Participants n=2 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Region of Enrollment Germany	6 Participants n=74 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	1 Participants n=42 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=26 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=10 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	7 Participants n=152 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.
Region of Enrollment Spain	6 Participants n=74 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	5 Participants n=42 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=26 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants n=10 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	0 Participants Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.	11 Participants n=152 Participants • Cohort 5 participants had progressed following initial treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are presented as Initial Treatment for Cohorts 1, 2, 3 \& 4, and Retreatment for Cohort 5.

PRIMARY outcome

Timeframe: Up to 60 months

Population: The Full Analysis Set is defined as participants who received TIL that met the manufacturing product specifications.

Outcome measures

Outcome measures
Measure	Cohort 3 n=70 Participants LN-145 in combination with pembrolizumab in participants who have not received any therapies other than prior chemoradiation or surgery for loco-regional disease.	Cohort 2 n=37 Participants LN-145 monotherapy in participants who have previously received a PD-1/PD-L1 checkpoint inhibitor either as monotherapy or combination therapy.
Cohort 1 and 2: Objective Response Rate	15 Participants	5 Participants

PRIMARY outcome

Timeframe: Up to 60 months

Population: The Safety Analysis Set is defined as participants who received TIL.

To characterize the safety profile of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by incidence of adverse events.

Outcome measures

Outcome measures
Measure	Cohort 3 n=26 Participants LN-145 in combination with pembrolizumab in participants who have not received any therapies other than prior chemoradiation or surgery for loco-regional disease.	Cohort 2 LN-145 monotherapy in participants who have previously received a PD-1/PD-L1 checkpoint inhibitor either as monotherapy or combination therapy.
Cohort 3: Adverse Events	26 Participants	—

PRIMARY outcome

Timeframe: Up to 60 months

Population: The Safety Analysis Set is defined as participants who received TIL.

To explore the safety profile of LN-145 in previously enrolled participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by incidence of adverse events.

Outcome measures

Outcome measures
Measure	Cohort 3 n=10 Participants LN-145 in combination with pembrolizumab in participants who have not received any therapies other than prior chemoradiation or surgery for loco-regional disease.	Cohort 2 LN-145 monotherapy in participants who have previously received a PD-1/PD-L1 checkpoint inhibitor either as monotherapy or combination therapy.
Cohort 4: Adverse Events	10 Participants	—

PRIMARY outcome

Timeframe: Up to 60 months

Population: The Full Analysis Set is defined as participants who received TIL that met the manufacturing product specifications.

To explore the efficacy of LN-145 in previously enrolled participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR).

Outcome measures

Outcome measures
Measure	Cohort 3 n=9 Participants LN-145 in combination with pembrolizumab in participants who have not received any therapies other than prior chemoradiation or surgery for loco-regional disease.	Cohort 2 LN-145 monotherapy in participants who have previously received a PD-1/PD-L1 checkpoint inhibitor either as monotherapy or combination therapy.
Cohort 4: Efficacy/Objective Response Rate	2 Participants	—

PRIMARY outcome

Timeframe: Up to 60 months

Population: The Safety Analysis Set is defined as participants who received TIL.

To explore the safety profile of LN-145 in re-treated participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by incidence of adverse events.

Outcome measures

Outcome measures
Measure	Cohort 3 n=2 Participants LN-145 in combination with pembrolizumab in participants who have not received any therapies other than prior chemoradiation or surgery for loco-regional disease.	Cohort 2 LN-145 monotherapy in participants who have previously received a PD-1/PD-L1 checkpoint inhibitor either as monotherapy or combination therapy.
Cohort 5: Adverse Events	2 Participants	—

PRIMARY outcome

Timeframe: Up to 60 months

Population: The Full Analysis Set is defined as participants who received TIL that met the manufacturing product specifications.

To explore the efficacy of LN-145 in re-treated participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR).

Outcome measures

Outcome measures
Measure	Cohort 3 n=2 Participants LN-145 in combination with pembrolizumab in participants who have not received any therapies other than prior chemoradiation or surgery for loco-regional disease.	Cohort 2 LN-145 monotherapy in participants who have previously received a PD-1/PD-L1 checkpoint inhibitor either as monotherapy or combination therapy.
Cohort 5: Efficacy/Objective Response Rate	0 Participants	—

SECONDARY outcome

Timeframe: Up to 60 months

Population: The Full Analysis Set is defined as participants who received TIL that met the manufacturing product specifications.

To evaluate the efficacy parameters of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing duration of response (DOR) as assessed by the Investigator per RECIST v1.1

Outcome measures

Outcome measures
Measure	Cohort 3 n=70 Participants LN-145 in combination with pembrolizumab in participants who have not received any therapies other than prior chemoradiation or surgery for loco-regional disease.	Cohort 2 n=37 Participants LN-145 monotherapy in participants who have previously received a PD-1/PD-L1 checkpoint inhibitor either as monotherapy or combination therapy.
Cohort 1 and 2: Duration of Response	6.8 months Interval 2.5 to Insufficient number of participants with events, therefore the 95% Confidence Interval could not be determined.	6.7 months Interval 4.2 to Insufficient number of participants with events, therefore the 95% Confidence Interval could not be determined.

SECONDARY outcome

Timeframe: Up to 60 months

Population: The Full Analysis Set is defined as participants who received TIL that met the manufacturing product specifications.

To evaluate the efficacy parameters of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing disease control rate (DCR) as assessed by the Investigator per RECIST v1.1.

Outcome measures

Outcome measures
Measure	Cohort 3 n=70 Participants LN-145 in combination with pembrolizumab in participants who have not received any therapies other than prior chemoradiation or surgery for loco-regional disease.	Cohort 2 n=37 Participants LN-145 monotherapy in participants who have previously received a PD-1/PD-L1 checkpoint inhibitor either as monotherapy or combination therapy.
Cohort 1 and 2: Disease Control Rate	43 Participants	23 Participants

SECONDARY outcome

Timeframe: Up to 60 months

Population: The Full Analysis Set is defined as participants who received TIL that met the manufacturing product specifications.

To evaluate the efficacy parameters of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing progression-free survival (PFS) as assessed by the Investigator per RECIST v1.1

Outcome measures

Outcome measures
Measure	Cohort 3 n=70 Participants LN-145 in combination with pembrolizumab in participants who have not received any therapies other than prior chemoradiation or surgery for loco-regional disease.	Cohort 2 n=37 Participants LN-145 monotherapy in participants who have previously received a PD-1/PD-L1 checkpoint inhibitor either as monotherapy or combination therapy.
Cohort 1 and 2: Progression-Free Survival	2.8 months Interval 2.3 to 4.1	2.8 months Interval 1.5 to 2.9

SECONDARY outcome

Timeframe: Up to 60 months

Population: The Full Analysis Set is defined as participants who received TIL that met the manufacturing product specifications.

To evaluate overall survival (OS) in participants with recurrent, metastatic, or persistent cervical carcinoma

Outcome measures

Outcome measures
Measure	Cohort 3 n=70 Participants LN-145 in combination with pembrolizumab in participants who have not received any therapies other than prior chemoradiation or surgery for loco-regional disease.	Cohort 2 n=37 Participants LN-145 monotherapy in participants who have previously received a PD-1/PD-L1 checkpoint inhibitor either as monotherapy or combination therapy.
Cohort 1 and 2: Overall Survival	8.8 months Interval 6.7 to 11.4	8.2 months Interval 4.0 to 10.3

SECONDARY outcome

Timeframe: Up to 60 months

Population: The Safety Analysis Set is defined as participants who received TIL.

To characterize the safety profile of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by incidence of adverse events

Outcome measures

Outcome measures
Measure	Cohort 3 n=74 Participants LN-145 in combination with pembrolizumab in participants who have not received any therapies other than prior chemoradiation or surgery for loco-regional disease.	Cohort 2 n=42 Participants LN-145 monotherapy in participants who have previously received a PD-1/PD-L1 checkpoint inhibitor either as monotherapy or combination therapy.
Cohort 1 and 2: Adverse Events	74 Participants	42 Participants

SECONDARY outcome

Timeframe: Up to 60 months

Population: The Full Analysis Set for Cohort 3 is defined as participants who received at least 1 dose of pembolizumab and TIL that met the manufacturing product specifications.

To evaluate the efficacy of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per RECIST v1.1

Outcome measures

Outcome measures
Measure	Cohort 3 n=25 Participants LN-145 in combination with pembrolizumab in participants who have not received any therapies other than prior chemoradiation or surgery for loco-regional disease.	Cohort 2 LN-145 monotherapy in participants who have previously received a PD-1/PD-L1 checkpoint inhibitor either as monotherapy or combination therapy.
Cohort 3: Objective Response Rate	13 Participants	—

SECONDARY outcome

Timeframe: Up to 60 months

Population: The Full Analysis Set for Cohort 3 is defined as participants who received at least 1 dose of pembrolizumab and TIL that met the manufacturing product specifications.

To evaluate the efficacy of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing duration of response (DOR) as assessed by the Investigator per RECIST v1.1.

Outcome measures

Outcome measures
Measure	Cohort 3 n=25 Participants LN-145 in combination with pembrolizumab in participants who have not received any therapies other than prior chemoradiation or surgery for loco-regional disease.	Cohort 2 LN-145 monotherapy in participants who have previously received a PD-1/PD-L1 checkpoint inhibitor either as monotherapy or combination therapy.
Cohort 3: Duration of Response	NA months Interval 4.4 to Insufficient number of participants with events, therefore the Median and 95% Confidence Interval were not reached	—

SECONDARY outcome

Timeframe: Up to 60 months

Population: The Full Analysis Set for Cohort 3 is defined as participants who have received at least 1 dose of pembrolizumab and TIL that met the manufacturing product specifications.

To evaluate the efficacy of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing disease control rate (DCR) as assessed by the Investigator per RECIST v1.1.

Outcome measures

Outcome measures
Measure	Cohort 3 n=25 Participants LN-145 in combination with pembrolizumab in participants who have not received any therapies other than prior chemoradiation or surgery for loco-regional disease.	Cohort 2 LN-145 monotherapy in participants who have previously received a PD-1/PD-L1 checkpoint inhibitor either as monotherapy or combination therapy.
Cohort 3: Disease Control Rate	23 Participants	—

SECONDARY outcome

Timeframe: Up to 60 months

Population: The Full Analysis Set for Cohort 3 is defined as participants who have received at least 1 dose of pembrolizumab and TIL that met the manufacturing product specifications.

To evaluate the efficacy of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing progression-free survival (PFS) as assessed by the Investigator per RECIST v1.1.

Outcome measures

Outcome measures
Measure	Cohort 3 n=25 Participants LN-145 in combination with pembrolizumab in participants who have not received any therapies other than prior chemoradiation or surgery for loco-regional disease.	Cohort 2 LN-145 monotherapy in participants who have previously received a PD-1/PD-L1 checkpoint inhibitor either as monotherapy or combination therapy.
Cohort 3: Progression-Free Survival	6.2 months Interval 3.3 to Insufficient number of participants with events, therefore the 95% Confidence Interval could not be determined.	—

SECONDARY outcome

Timeframe: Up to 60 months

Population: The Full Analysis Set for Cohort 3 is defined as participants who have received at least 1 dose of pembrolizumab and TIL that met the manufacturing product specifications.

To evaluate overall survival (OS) in participants with recurrent, metastatic, or persistent cervical carcinoma.

Outcome measures

Outcome measures
Measure	Cohort 3 n=25 Participants LN-145 in combination with pembrolizumab in participants who have not received any therapies other than prior chemoradiation or surgery for loco-regional disease.	Cohort 2 LN-145 monotherapy in participants who have previously received a PD-1/PD-L1 checkpoint inhibitor either as monotherapy or combination therapy.
Cohort 3: Overall Survival	27.7 months Interval 15.2 to 41.6	—

Adverse Events

Cohort 1

Serious events: 31 serious events

Other events: 74 other events

Deaths: 63 deaths

Cohort 2

Serious events: 20 serious events

Other events: 42 other events

Deaths: 34 deaths

Cohort 3

Serious events: 18 serious events

Other events: 26 other events

Deaths: 17 deaths

Cohort 4

Serious events: 7 serious events

Other events: 10 other events

Deaths: 9 deaths

Cohort 5

Serious events: 1 serious events

Other events: 2 other events

Deaths: 2 deaths

Serious adverse events

Serious adverse events
Measure	Cohort 1 n=74 participants at risk LN-145 monotherapy in participants who have progressed during or following systemic therapy; this cohort is no longer open for enrollment.	Cohort 2 n=42 participants at risk LN-145 monotherapy in participants who have previously received a PD-1/PD-L1 checkpoint inhibitor either as monotherapy or combination therapy.	Cohort 3 n=26 participants at risk LN-145 in combination with pembrolizumab in participants who have not received any therapies other than prior chemoradiation or surgery for loco-regional disease.	Cohort 4 n=10 participants at risk LN-145 monotherapy in previously enrolled participants who do not meet requirements for inclusion in the other study cohorts; this cohort is not open for enrollment.	Cohort 5 n=2 participants at risk LN-145 monotherapy as a re-treatment.
Blood and lymphatic system disorders Anaemia	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Blood and lymphatic system disorders Disseminated intravascular coagulation	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Blood and lymphatic system disorders Febrile neutropenia	6.8% 5/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.1% 3/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Blood and lymphatic system disorders Leukopenia	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Blood and lymphatic system disorders Lymph node pain	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Blood and lymphatic system disorders Neutropenia	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.1% 3/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Blood and lymphatic system disorders Pancytopenia	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Blood and lymphatic system disorders Thrombocytopenia	5.4% 4/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.1% 3/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Acute myocardial infarction	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Atrial fibrillation	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Atrioventricular block	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Cardiac failure congestive	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Myocarditis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Pericardial effusion	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Sinus tachycardia	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Tachyarrhythmia	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Tachycardia	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Ventricular fibrillation	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Endocrine disorders Hyperthyroidism	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Endocrine disorders Hypothyroidism	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Eye disorders Vision blurred	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Abdominal pain	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Colitis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Diarrhoea	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Enterovesical fistula	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Nausea	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	50.0% 1/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Small intestinal obstruction	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Upper gastrointestinal haemorrhage	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Vomiting	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	50.0% 1/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Asthenia	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Chest discomfort	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Malaise	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Multiple organ dysfunction syndrome	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Non-cardiac chest pain	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Pyrexia	6.8% 5/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Systemic inflammatory response syndrome	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Hepatobiliary disorders Acute hepatic failure	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Hepatobiliary disorders Hypertransaminasaemia	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Immune system disorders Anaphylactic reaction	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Immune system disorders Cytokine release syndrome	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Bacteraemia	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations COVID-19	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Latent tuberculosis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Pneumonia	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Pyelonephritis	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Respiratory syncytial virus infection	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Sepsis	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Injury, poisoning and procedural complications Infusion related reaction	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Troponin increased	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Urine output decreased	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations White blood cell count increased	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Dehydration	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	50.0% 1/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Diabetic ketoacidosis	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Hyponatraemia	4.1% 3/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Musculoskeletal and connective tissue disorders Flank pain	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Musculoskeletal and connective tissue disorders Pain in extremity	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Epstein-Barr virus associated lymphoproliferative disorder	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Depressed level of consciousness	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Encephalopathy	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Immune effector cell-associated neurotoxicity syndrome	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Metabolic encephalopathy	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Presyncope	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Seizure	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Syncope	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Psychiatric disorders Anxiety	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Psychiatric disorders Mental status changes	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Renal and urinary disorders Acute kidney injury	5.4% 4/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	14.3% 6/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Renal and urinary disorders Haematuria	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Renal and urinary disorders Renal vascular thrombosis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Renal and urinary disorders Urinary fistula	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Renal and urinary disorders Urinary tract obstruction	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Reproductive system and breast disorders Vaginal haemorrhage	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Dyspnoea	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Hypoxia	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Pulmonary hypertension	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Pulmonary oedema	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.5% 3/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Acute febrile neutrophilic dermatosis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Vascular disorders Capillary leak syndrome	8.1% 6/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Vascular disorders Embolism	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Vascular disorders Haematoma	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Vascular disorders Hypertension	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Vascular disorders Hypotension	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.

Other adverse events

Other adverse events
Measure	Cohort 1 n=74 participants at risk LN-145 monotherapy in participants who have progressed during or following systemic therapy; this cohort is no longer open for enrollment.	Cohort 2 n=42 participants at risk LN-145 monotherapy in participants who have previously received a PD-1/PD-L1 checkpoint inhibitor either as monotherapy or combination therapy.	Cohort 3 n=26 participants at risk LN-145 in combination with pembrolizumab in participants who have not received any therapies other than prior chemoradiation or surgery for loco-regional disease.	Cohort 4 n=10 participants at risk LN-145 monotherapy in previously enrolled participants who do not meet requirements for inclusion in the other study cohorts; this cohort is not open for enrollment.	Cohort 5 n=2 participants at risk LN-145 monotherapy as a re-treatment.
Investigations Blood culture positive	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Blood lactate dehydrogenase increased	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.5% 3/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Blood magnesium decreased	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Blood pH decreased	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Blood phosphorus decreased	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Blood thyroid stimulating hormone decreased	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Blood thyroid stimulating hormone increased	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Blood uric acid decreased	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Blood uric acid increased	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Blood urine present	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Breath sounds abnormal	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations C-reactive protein increased	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Candida test positive	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Cardiac murmur	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Ejection fraction decreased	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Electrocardiogram QT prolonged	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Electrocardiogram T wave abnormal	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Faecal volume increased	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Gamma-glutamyltransferase increased	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Gastric pH decreased	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Interleukin level increased	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations International normalised ratio increased	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Lymphocyte count increased	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Myocardial strain imaging abnormal	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Neutrophil count increased	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Oxygen saturation decreased	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Parainfluenza virus test positive	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Protein total decreased	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Prothrombin level decreased	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Thyroxine decreased	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Thyroxine free decreased	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Transaminases increased	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Troponin I increased	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Troponin T increased	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Urine output decreased	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Weight decreased	5.4% 4/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	23.1% 6/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	50.0% 1/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Weight increased	10.8% 8/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.5% 3/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations White blood cell count increased	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Alkalosis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Appetite disorder	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Decreased appetite	13.5% 10/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	14.3% 6/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	53.8% 14/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	50.0% 1/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Dehydration	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Fluid retention	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	9.5% 4/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Renal and urinary disorders Renal failure	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	20.0% 2/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Hypercholesterolaemia	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Hyperglycaemia	5.4% 4/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	20.0% 2/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Hyperkalaemia	4.1% 3/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.5% 3/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Hypermagnesaemia	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Hyperphosphataemia	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Hypertriglyceridaemia	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Hyperuricaemia	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.5% 3/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Hypervolaemia	5.4% 4/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Hypoalbuminaemia	17.6% 13/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.1% 3/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	30.0% 3/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Hypocalcaemia	18.9% 14/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	9.5% 4/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.5% 3/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	20.0% 2/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Hypoglycaemia	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Hypokalaemia	18.9% 14/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	16.7% 7/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	30.8% 8/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	30.0% 3/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Hypomagnesaemia	24.3% 18/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	16.7% 7/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	26.9% 7/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Hyponatraemia	5.4% 4/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	9.5% 4/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.5% 3/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	20.0% 2/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Hypophagia	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Hypophosphataemia	28.4% 21/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	26.2% 11/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	38.5% 10/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	40.0% 4/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Hypouricaemia	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Iron deficiency	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Metabolic acidosis	4.1% 3/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Renal and urinary disorders Urinary incontinence	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	23.1% 6/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Refeeding syndrome	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Metabolism and nutrition disorders Weight fluctuation	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Musculoskeletal and connective tissue disorders Arthralgia	5.4% 4/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	30.8% 8/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Musculoskeletal and connective tissue disorders Back pain	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	19.2% 5/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Musculoskeletal and connective tissue disorders Bone pain	4.1% 3/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Musculoskeletal and connective tissue disorders Flank pain	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	19.2% 5/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Renal and urinary disorders Urinary retention	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Musculoskeletal and connective tissue disorders Groin pain	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Musculoskeletal and connective tissue disorders Limb discomfort	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Musculoskeletal and connective tissue disorders Muscle spasms	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Musculoskeletal and connective tissue disorders Muscular weakness	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	23.1% 6/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Musculoskeletal and connective tissue disorders Musculoskeletal stiffness	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Musculoskeletal and connective tissue disorders Myalgia	5.4% 4/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	19.2% 5/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.5% 3/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Musculoskeletal and connective tissue disorders Pain in extremity	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.1% 3/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	19.2% 5/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Musculoskeletal and connective tissue disorders Pain in jaw	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Musculoskeletal and connective tissue disorders Spinal pain	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Benign neoplasm of skin	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Amnesia	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Disturbance in attention	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Dizziness	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.9% 5/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	34.6% 9/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Dysaesthesia	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Dysgeusia	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.5% 3/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Encephalopathy	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Headache	18.9% 14/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	16.7% 7/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	50.0% 13/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	20.0% 2/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Hypoaesthesia	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Lethargy	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Migraine	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Muscle spasticity	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Neurological symptom	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Neuropathy peripheral	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Paraesthesia	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Peripheral motor neuropathy	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Peripheral sensory neuropathy	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Presyncope	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Seizure	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Somnolence	4.1% 3/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.5% 3/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Nervous system disorders Tremor	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.1% 3/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Psychiatric disorders Agitation	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Psychiatric disorders Anxiety	9.5% 7/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	23.1% 6/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Psychiatric disorders Confusional state	4.1% 3/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	9.5% 4/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Psychiatric disorders Delirium	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Psychiatric disorders Delusion	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Psychiatric disorders Depression	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	15.4% 4/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Psychiatric disorders Disorientation	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Psychiatric disorders Hallucination	6.8% 5/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Psychiatric disorders Insomnia	5.4% 4/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	34.6% 9/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Psychiatric disorders Mental status changes	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Psychiatric disorders Restlessness	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Renal and urinary disorders Acute kidney injury	9.5% 7/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	9.5% 4/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.5% 3/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Renal and urinary disorders Anuria	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Renal and urinary disorders Bladder discomfort	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Renal and urinary disorders Cystitis haemorrhagic	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Renal and urinary disorders Cystitis noninfective	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Renal and urinary disorders Dysuria	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	26.9% 7/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Renal and urinary disorders Haematuria	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	9.5% 4/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	30.8% 8/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Renal and urinary disorders Leukocyturia	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Renal and urinary disorders Micturition urgency	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Renal and urinary disorders Myoglobinuria	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Renal and urinary disorders Nephritic syndrome	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Renal and urinary disorders Nephrolithiasis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Renal and urinary disorders Oliguria	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Renal and urinary disorders Pollakiuria	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	23.1% 6/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Renal and urinary disorders Polyuria	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Renal and urinary disorders Proteinuria	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	30.0% 3/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Blood and lymphatic system disorders Anaemia	66.2% 49/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	57.1% 24/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	76.9% 20/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	70.0% 7/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	50.0% 1/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Blood and lymphatic system disorders Coagulopathy	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Blood and lymphatic system disorders Febrile neutropenia	35.1% 26/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	21.4% 9/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	42.3% 11/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	20.0% 2/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Blood and lymphatic system disorders Granulocytopenia	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Blood and lymphatic system disorders Leukocytosis	5.4% 4/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Blood and lymphatic system disorders Leukopenia	31.1% 23/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	9.5% 4/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	23.1% 6/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	50.0% 5/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Blood and lymphatic system disorders Lymphopenia	23.0% 17/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	30.8% 8/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	20.0% 2/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Blood and lymphatic system disorders Monocytopenia	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Blood and lymphatic system disorders Neutropenia	35.1% 26/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	16.7% 7/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	53.8% 14/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	60.0% 6/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Blood and lymphatic system disorders Pancytopenia	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Blood and lymphatic system disorders Thrombocytopenia	52.7% 39/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	61.9% 26/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	57.7% 15/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	70.0% 7/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	50.0% 1/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Angina pectoris	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Atrial fibrillation	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Atrial flutter	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Cardiac failure	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Cardiac failure congestive	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Cardiomyopathy	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Cardiorenal syndrome	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Myocarditis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Palpitations	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.5% 3/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Pericardial effusion	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Right ventricular dysfunction	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Sinus bradycardia	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Sinus tachycardia	17.6% 13/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	9.5% 4/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	46.2% 12/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	30.0% 3/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Supraventricular tachycardia	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Tachyarrhythmia	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Tachycardia	21.6% 16/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	14.3% 6/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	19.2% 5/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Tricuspid valve disease	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Cardiac disorders Ventricular tachycardia	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Congenital, familial and genetic disorders Left ventricle outflow tract obstruction	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Ear and labyrinth disorders Motion sickness	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Ear and labyrinth disorders Tinnitus	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Ear and labyrinth disorders Vertigo	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Endocrine disorders Hyperthyroidism	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Endocrine disorders Hypothyroidism	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Eye disorders Blepharitis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Eye disorders Conjunctival haemorrhage	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Eye disorders Conjunctival hyperaemia	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Eye disorders Dry eye	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.5% 3/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Eye disorders Eye haematoma	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Eye disorders Eye pain	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Eye disorders Ocular hyperaemia	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Eye disorders Vision blurred	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	15.4% 4/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Eye disorders Visual impairment	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Eye disorders Vitreous haemorrhage	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Abdominal discomfort	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Abdominal distension	4.1% 3/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	15.4% 4/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Abdominal pain	4.1% 3/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	34.6% 9/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	50.0% 1/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Abdominal pain lower	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Abdominal pain upper	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.5% 3/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Anal haemorrhage	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Anal incontinence	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Ascites	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.1% 3/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Constipation	12.2% 9/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.9% 5/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	57.7% 15/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	50.0% 1/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Defaecation urgency	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Diarrhoea	39.2% 29/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	31.0% 13/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	38.5% 10/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	20.0% 2/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Dry mouth	5.4% 4/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Duodenal obstruction	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Duodenal stenosis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Dyspepsia	4.1% 3/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.5% 3/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Dysphagia	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Enteritis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Epigastric discomfort	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Flatulence	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Gastrointestinal disorder	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Gastrooesophageal reflux disease	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Gingival bleeding	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Gingival pain	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Glossodynia	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Haematochezia	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Haemorrhoids	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Ileus	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Lip dry	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Melaena	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Nausea	25.7% 19/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.1% 3/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	84.6% 22/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Obstruction gastric	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Oral dysaesthesia	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Oral mucosal blistering	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Oral pain	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Proctalgia	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Rectal haemorrhage	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Stomatitis	8.1% 6/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.5% 3/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Tooth disorder	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Toothache	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Gastrointestinal disorders Vomiting	29.7% 22/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	21.4% 9/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	69.2% 18/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	30.0% 3/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	50.0% 1/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Asthenia	8.1% 6/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Catheter site pain	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Chest pain	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Chills	60.8% 45/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	59.5% 25/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	88.5% 23/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	50.0% 5/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Complication associated with device	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Crepitations	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Face oedema	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.5% 3/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Facial discomfort	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Fatigue	21.6% 16/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.9% 5/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	65.4% 17/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	20.0% 2/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Generalised oedema	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Hypothermia	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Influenza like illness	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Localised oedema	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Malaise	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Medical device discomfort	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Mucosal inflammation	5.4% 4/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Non-cardiac chest pain	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	20.0% 2/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Oedema	5.4% 4/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Oedema peripheral	14.9% 11/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	9.5% 4/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	38.5% 10/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	20.0% 2/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Pain	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.5% 3/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Peripheral swelling	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Puncture site pain	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Pyrexia	55.4% 41/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	31.0% 13/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	53.8% 14/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	60.0% 6/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Swelling	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Temperature intolerance	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Unevaluable event	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
General disorders Xerosis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Hepatobiliary disorders Cholelithiasis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Hepatobiliary disorders Drug-induced liver injury	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Hepatobiliary disorders Hepatitis acute	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Hepatobiliary disorders Hepatorenal syndrome	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Hepatobiliary disorders Hyperbilirubinaemia	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Hepatobiliary disorders Hypertransaminasaemia	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Immune system disorders Contrast media reaction	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Immune system disorders Cytokine release syndrome	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	16.7% 7/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	50.0% 1/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Immune system disorders Drug hypersensitivity	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Immune system disorders Hypersensitivity	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Immune system disorders Serum sickness	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Bacteraemia	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Bacterial infection	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Bacteriuria	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Bronchopulmonary aspergillosis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations COVID-19	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	15.4% 4/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Cellulitis	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Clostridium difficile colitis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Clostridium difficile infection	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Cytomegalovirus infection	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Device related infection	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Ear infection	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Enterocolitis infectious	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Folliculitis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Fungal disease carrier	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Genital herpes simplex	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations HCoV-HKU1 infection	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Herpes simplex	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Herpes simplex reactivation	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Infection	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Kidney infection	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Klebsiella infection	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Latent tuberculosis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Nasopharyngitis	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Pneumonia	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Pneumonia aspiration	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Pyelonephritis	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Rash pustular	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Respiratory syncytial virus infection	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Rhinitis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Scabies	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Sepsis	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Sinusitis	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Tinea infection	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Tooth infection	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Upper respiratory tract infection	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Urinary tract infection	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	14.3% 6/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.5% 3/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Vaginal infection	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Infections and infestations Wound infection	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Injury, poisoning and procedural complications Contusion	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Injury, poisoning and procedural complications Fall	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Injury, poisoning and procedural complications Gastrointestinal stoma complication	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Injury, poisoning and procedural complications Infusion related reaction	8.1% 6/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	14.3% 6/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	19.2% 5/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Injury, poisoning and procedural complications Tooth fracture	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Injury, poisoning and procedural complications Transfusion reaction	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Injury, poisoning and procedural complications Vascular access complication	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.1% 3/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Injury, poisoning and procedural complications Wound dehiscence	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Activated partial thromboplastin time prolonged	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Alanine aminotransferase increased	14.9% 11/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	16.7% 7/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.5% 3/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Aspartate aminotransferase increased	13.5% 10/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	16.7% 7/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	19.2% 5/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	20.0% 2/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Blood alkaline phosphatase	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Blood alkaline phosphatase increased	14.9% 11/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.9% 5/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.5% 3/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Blood bicarbonate decreased	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Blood bilirubin increased	5.4% 4/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Blood chloride decreased	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Blood creatine phosphokinase decreased	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Blood creatine phosphokinase increased	4.1% 3/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Investigations Blood creatinine increased	12.2% 9/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	9.5% 4/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	15.4% 4/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Renal and urinary disorders Urinary tract obstruction	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Reproductive system and breast disorders Breast pain	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Reproductive system and breast disorders Dyspareunia	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Reproductive system and breast disorders Genital disorder	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Reproductive system and breast disorders Intermenstrual bleeding	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Reproductive system and breast disorders Pelvic pain	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Reproductive system and breast disorders Vaginal haemorrhage	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	15.4% 4/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Reproductive system and breast disorders Vulvovaginal pruritus	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Reproductive system and breast disorders Vulvovaginal swelling	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Aphonia	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Atelectasis	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Cough	13.5% 10/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	9.5% 4/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	38.5% 10/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Dysphonia	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Dyspnoea	25.7% 19/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	23.8% 10/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	53.8% 14/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	20.0% 2/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Epistaxis	5.4% 4/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Hiccups	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Hypoxia	27.0% 20/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	14.3% 6/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	57.7% 15/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	20.0% 2/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Laryngeal inflammation	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Laryngeal oedema	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Nasal congestion	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	23.1% 6/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Nasal discomfort	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Oropharyngeal erythema	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	4.1% 3/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	30.8% 8/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Painful respiration	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Pleural effusion	10.8% 8/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	9.5% 4/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	15.4% 4/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Pneumonitis	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Productive cough	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Pulmonary oedema	5.4% 4/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Pulmonary pain	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Rales	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Rhinitis allergic	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.5% 3/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Rhonchi	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Sneezing	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Tachypnoea	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Upper-airway cough syndrome	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Respiratory, thoracic and mediastinal disorders Wheezing	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Alopecia	23.0% 17/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	23.8% 10/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	46.2% 12/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	30.0% 3/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Blister	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Capillaritis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Dermatitis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Dermatitis acneiform	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Dermatitis atopic	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Dermatitis bullous	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Dermatitis exfoliative generalised	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Drug eruption	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Dry skin	4.1% 3/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.5% 3/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Ecchymosis	2.7% 2/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Eczema	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Erythema	5.4% 4/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Hyperhidrosis	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Intertrigo	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Livedo reticularis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Nail discolouration	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Nail disorder	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Night sweats	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Petechiae	6.8% 5/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Photosensitivity reaction	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Pruritus	6.8% 5/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	14.3% 6/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	26.9% 7/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Rash	9.5% 7/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	9.5% 4/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	11.5% 3/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Rash erythematous	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Rash macular	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Rash maculo-papular	5.4% 4/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	14.3% 6/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	26.9% 7/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Rash pruritic	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Seborrhoeic dermatitis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Skin disorder	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Skin odour abnormal	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Skin reaction	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Skin ulcer	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Skin and subcutaneous tissue disorders Urticaria	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Vascular disorders Capillary leak syndrome	6.8% 5/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Vascular disorders Deep vein thrombosis	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	4.8% 2/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Vascular disorders Embolism	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	3.8% 1/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Vascular disorders Flushing	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Vascular disorders Haemorrhage	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Vascular disorders Hot flush	4.1% 3/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	7.7% 2/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Vascular disorders Hypertension	6.8% 5/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	21.4% 9/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	26.9% 7/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	10.0% 1/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Vascular disorders Hypotension	44.6% 33/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	40.5% 17/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	50.0% 13/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	20.0% 2/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Vascular disorders Lymphoedema	1.4% 1/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Vascular disorders Phlebitis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.
Vascular disorders Superficial vein thrombosis	0.00% 0/74 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	2.4% 1/42 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/26 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/10 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.	0.00% 0/2 • From enrollment to end of follow-up (up to 60 months) Treatment-emergent adverse events (TEAEs), clinical laboratory data assessments, serious adverse events(SAEs), and adverse events (AEs) were collected and evaluated for the duration of the study until resolution or permanent sequelae. The Safety Analysis Set is defined as participants who received TIL.

Additional Information

Chief Medical Officer

Iovance Biotherapeutics

Phone: 1-844-845-4682

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place